secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0000950170-23-059381
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen Q3 revenue up 155% to $40.1M; roxadustat China sales up 31%
--------------------------------------------------------------------

- Net loss of $63.6M ($0.65 loss per share) vs $91.7M ($0.98) YoY; restructuring charge of $12.6M.
- Roxadustat net product revenue in China reached $29.4M, up 69% YoY; total China sales $77.1M (up 31%), driven by 37% volume growth.
- Annualized cost reduction of $120M implemented; cash of $283.0M expected to fund operations into 2026.
- Pamrevlumab LAPIS Phase 3 topline data expected Q1 2024; PanCAN Phase 2/3 data in 1H 2024.
- sNDA for roxadustat in chemotherapy-induced anemia accepted in China; approval decision mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017023059381/0000950170-23-059381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017023059381/fgen-20231106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-059381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer